AstraZeneca said it is cutting several late-stage and mid-stage programs after disappointing efficacy, including discontinuing a Phase 2 asthma trial of atuliflapon, a FLAP inhibitor. The company reported that the trial was halted “due to efficacy” and atuliflapon was removed from its pipeline. In addition to the asthma setback, AstraZeneca disclosed that it ended work on other programs, including a Phase 2 evaluation of ALXN2420 for acromegaly, a Phase 1 study of the ANGPTL3 inhibitor AZD1705 for dyslipidemia, and a Phase 1 siRNA candidate AZD6912 for rheumatoid arthritis. The portfolio recalibration underscores how quickly pipeline bets can be reprioritized once efficacy signals disappoint, especially for lifecycle and rare-disease strategies that require sustained capital commitment.